利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.055 秒)

    Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
    1.
    发明申请
    Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效
    心肌梗塞，中风和PAOD的易感基因; 治疗方法

    公开(公告)号：US20070280917A1

    公开(公告)日：2007-12-06

    申请号：US11270804

    申请日：2005-11-09

    申请人： Anna Helgadottir ,  Hakon Hakonarson ,  Jeffrey Gulcher ,  Mark Gurney

    发明人： Anna Helgadottir ,  Hakon Hakonarson ,  Jeffrey Gulcher ,  Mark Gurney

    IPC分类号： A61K31/47 ,  A61K31/20 ,  A61K38/00 ,  C12Q1/68 ,  A61K38/43 ,  A61K31/33

    CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

    摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

    摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。

    Human schizophrenia gene
    9.
    发明申请
    Human schizophrenia gene 审中-公开
    人精神分裂症基因

    公开(公告)号：US20050208527A1

    公开(公告)日：2005-09-22

    申请号：US10995011

    申请日：2004-11-22

    申请人： Hreinn Stefansson ,  Valgerdur Steinthorsdottir ,  Jeffrey Gulcher ,  Mark Gurney ,  Thorkell Andresson

    发明人： Hreinn Stefansson ,  Valgerdur Steinthorsdottir ,  Jeffrey Gulcher ,  Mark Gurney ,  Thorkell Andresson

    IPC分类号： A61K38/17 ,  A61K38/18 ,  C12Q1/68

    CPC分类号： C07K14/4756 ,  A01K67/0276 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0356 ,  A61K38/00 ,  C07K2319/00 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N2500/04 ,  G01N2800/2835

    摘要： Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia. Also described are hypomorphic mice for use in identifying phenotypes associated with schizophrenia, as well as for use in assessing agents of interest for neuroleptic activity and for potential therapeutic use for treatment of schizophrenia.

    摘要翻译： 公开了包含神经调节蛋白1基因（NRG1）和编码NRG1多肽的核酸。 还描述了编码NRG1多肽的相关核酸; NRG1多肽; 结合NRG1多肽的抗体; 精神分裂症易感性诊断方法; 用于改变NRG1多肽的活性或鉴定NRG1结合剂的试剂的测定法和通过测定鉴定的试剂或结合剂; NRG1治疗剂，包括NRG1核酸，NRG1多肽或改变NRG1多肽活性的试剂; 包含NRG1治疗剂的药物组合物; 以及精神分裂症治疗方法。 描述了在受影响个体中具有共同核心单体型的新型单元型，以及它们在筛选易感性精神分裂症的方法中的用途。 还描述了用于鉴定与精神分裂症相关的表型的同型小鼠，以及用于评估精神兴奋活性感兴趣的药物和用于治疗精神分裂症的潜在治疗用途。